Kiniksa Pharmaceuticals Ltd (KNSA) — Capital Reinvestment Ratio
Kiniksa Pharmaceuticals Ltd (KNSA) has a Capital Reinvestment Ratio of 0.00x as of March 2026, meaning it reinvests 0% of its operating cash flow ($50.20 Million) in capital expenditures ($161.00K). See debt-free asset ratio of Kiniksa Pharmaceuticals Ltd to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Kiniksa Pharmaceuticals Ltd Capital Reinvestment Ratio (2022–2025)
This chart tracks Kiniksa Pharmaceuticals Ltd's Capital Reinvestment Ratio across 4 annual periods. Check how aggressively does Kiniksa Pharmaceuticals Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Kiniksa Pharmaceuticals Ltd (2022–2025)
Year-by-year Capital Reinvestment Ratio for Kiniksa Pharmaceuticals Ltd from 2022 to 2025. For live market cap and broader valuation context, see Kiniksa Pharmaceuticals Ltd market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.01x | $25.69 Million | $277.00K | ▲ +0.0% |
| 2024 | 0.01x | $25.69 Million | $277.00K | ▲ +10.3% |
| 2023 | 0.01x | $13.30 Million | $130.00K | ▼ -45.9% |
| 2022 | 0.02x | $5.81 Million | $105.00K | — |